InSilico Medicine IP

Insilico Medicine is a clinical-stage biotechnology company that leverages generative artificial intelligence to accelerate drug discovery and development. The company's proprietary Pharma.AI platform integrates generative biology, chemistry, and clinical trial prediction to identify novel targets and design optimized molecular structures. Its lead candidate, INS018_055, is a first-in-class small molecule inhibitor for idiopathic pulmonary fibrosis and represents the first AI-discovered and AI-designed drug to enter Phase 2 clinical trials. Beyond its internal pipeline focused on fibrosis, oncology, and immunology, Insilico maintains strategic collaborations with global pharmaceutical leaders like Sanofi and Exelixis. The company operates globally with significant research hubs in the United States, China, and the United Arab Emirates.